Stem Cells and Exosomes Offer Hope for Kidneys Damaged by Cancer Therapy

Cancer medicine is saving more lives than ever, but the treatments themselves are quietly taking a toll on one of the body’s most vulnerable organs. A sweeping new review published in Holistic Integrative Oncology maps the growing problem of anticancer therapy-related renal injury, or ATRI, and examines whether cell-based and cell-derived therapies could finally give oncologists a way to protect the kidney without weakening the fight against the tumor. The verdict is cautiously optimistic: the biology is compelling, the preclinical data are mounting, but no such therapy has yet proven itself in a randomized trial involving cancer patients.

The scale of the problem is substantial. As survival from cancer lengthens and treatment regimens grow more intense, kidney injury has emerged as a major clinical issue that can compromise both prognosis and quality of life. The review, led by Zixuan Chen and colleagues at Tongren Hospital, Shanghai Jiao Tong University School of Medicine, together with Hua Sun at the University of Iowa, catalogs how nearly every major class of anticancer therapy inflicts a distinct pattern of renal damage. Conventional chemotherapeutics, molecular targeted agents, immune checkpoint inhibitors, and immune cell therapies each attack the kidney through different biological routes, making ATRI not a single disease but a family of injuries requiring tailored solutions.

Cisplatin, a cornerstone of chemotherapy for decades, remains one of the most notorious offenders. The drug accumulates preferentially in renal proximal tubular epithelial cells, partly through the organic cation transporter 2, where it triggers oxidative stress, mitochondrial dysfunction, and tubular apoptosis. Even with standard preventive measures such as hydration, cisplatin-associated acute kidney injury remains clinically common, and when poorly managed it can progress to renal fibrosis and chronic kidney disease. Molecular targeted drugs behave differently. Inhibitors of the vascular endothelial growth factor pathway frequently cause proteinuria and hypertension by disrupting the delicate crosstalk between podocytes and glomerular endothelial cells, sometimes culminating in thrombotic microangiopathy. Fibroblast growth factor receptor inhibitors produce a strikingly different signature: hyperphosphatemia occurs in roughly 60 to 70 percent of patients, reflecting interference with the FGF23-FGFR axis and impaired renal phosphate handling.

The immunotherapy era has added entirely new injury patterns. Immune checkpoint inhibitors, by dismantling peripheral immune tolerance, can provoke T-cell attacks on renal antigens, most commonly manifesting as acute interstitial nephritis with an estimated incidence of 3 to 5 percent. Recent multicenter work incorporating immunophenotyping suggests these nephritides may include separable inflammatory subtypes that respond differently to glucocorticoids, underscoring the need for precision classification. Meanwhile, chimeric antigen receptor T-cell therapy introduces kidney injury through an even more circuitous route. Acute kidney injury after CAR-T therapy occurs in roughly 5 to 33 percent of patients, with a pooled incidence of about 19 percent, driven largely by cytokine release syndrome, capillary leak, hemodynamic instability, and tumor lysis rather than direct drug toxicity.

Current management of all these injuries is largely reactive. Clinicians rely on monitoring serum creatinine, adjusting doses, pausing treatment, or administering steroids when immune-mediated nephritis appears. Each approach carries a cost. Serum creatinine is a lagging indicator that can miss early tubular injury, and dose reduction, while often the most effective nephroprotective move, may compromise antitumor efficacy and limit regimen intensity. As combination regimens integrating chemotherapy, targeted therapy, immunotherapy, and cellular immunotherapy become standard, overlapping injury pathways and drug interactions are stretching current management paradigms to their limits. What is missing, the authors argue, is a strategy that actively preserves nephron structure and function without interfering with cancer treatment.

Enter mesenchymal stem cells, or MSCs, the most widely studied cell type in translational kidney protection. Rather than differentiating into renal parenchymal cells, MSCs act mainly as mobile secretory units, sensing tissue injury cues and releasing bioactive factors and extracellular vesicles that reshape the local microenvironment. Their renoprotective repertoire spans three dimensions. They secrete anti-inflammatory mediators such as TSG-6, prostaglandin E2, and interleukin-10 that dampen excessive immune activation. They release trophic factors including hepatocyte growth factor and VEGF that reduce tubular cell apoptosis, and in one particularly striking mechanism they deliver functional mitochondria to injured tubular cells through tunneling nanotubes, rapidly restoring bioenergetic capacity. They also suppress profibrotic signaling through the TGF-beta1 and Smad axis, limiting the scarring that follows sustained injury. These properties map most directly onto cisplatin-associated nephrotoxicity, where tubular stress, oxidative damage, and mitochondrial dysfunction dominate.

Yet MSCs face two formidable barriers in oncology. The first is delivery: after systemic infusion, only a small fraction of administered cells reach and persist within the kidney, constraining efficacy and increasing variability. Image-guided regional administration has shown promise in preclinical studies but remains unstandardized. The second, and thornier, barrier is oncologic safety. Because MSCs modulate immune responses and promote angiogenic signaling, their influence on the tumor microenvironment is a genuine theoretical concern, and the nature of that concern shifts with treatment context. In patients receiving checkpoint inhibitors, MSC immunoregulation might either resolve renal immune toxicity or blunt checkpoint efficacy. In those on VEGF pathway inhibitors, pro-angiogenic signals could theoretically counteract the antitumor mechanism itself. The authors suggest that acceptable risk may differ between curative-intent and palliative settings, with a more permissive calculus justified when renal preservation directly determines treatment continuity.

Renal progenitor and precursor cells represent a fundamentally different reparative philosophy: instead of modulating inflammation, they aim to replace lost epithelial cells and reconstruct nephron structure. Advances in induced pluripotent stem cell technology have enabled the generation of human iPSC-derived nephron progenitor cells expressing developmental markers such as SIX2 and WT1, capable of differentiating toward podocyte-like and tubular epithelial phenotypes. In mouse models of cisplatin-induced injury, transplanted progenitors localize to damaged regions, contribute to epithelial repair, and secrete trophic factors supporting recovery. Urine-derived precursor-like cells expressing SOX9-related programs offer a noninvasive, autologous sourcing route that sidesteps immune rejection. But the bar for clinical implementation is high: stringent control of cell purity, differentiation stage, genomic stability, and non-tumorigenicity is essential, particularly because chemotherapy and targeted therapies impose genotoxic pressures that could destabilize transplanted cells.

Exosomes, nanoscale vesicles carrying proteins, nucleic acids, and lipids, are emerging as the leading cell-free alternative. MSC-derived exosomes recapitulate many benefits of their parent cells while avoiding risks of live-cell administration such as microvascular trapping and uncontrolled proliferation. Their phospholipid bilayer protects cargo, their small size and low immunogenicity favor systemic delivery, and the absence of a complete cellular genome substantially reduces proliferation concerns. Exosomal microRNAs can modulate apoptosis and inflammatory signaling in recipient renal cells, while antioxidant enzymes mitigate reactive oxygen species. Yet the review issues a clear warning: exosomes are not inherently safer. Tumor-derived exosomes can promote immune evasion and therapeutic resistance, with reports in renal cell carcinoma showing that exosomes from drug-resistant cells carry elevated PD-L1. Even MSC-derived exosomes may carry pro-angiogenic or therapy-resistance-promoting cargo depending on source cell state and manufacturing conditions. Rigorous cargo profiling, standardized characterization under MISEV2023 guidance, and validation in tumor-bearing models are prerequisites before clinical advancement.

The path forward, the authors conclude, requires coordinated advances across engineering, delivery, clinical stratification, trial design, and manufacturing. Future cell products will likely be bioengineered rather than unmodified, with gene editing and controlled preconditioning creating context-responsive cells activated only within injured renal tissue. Kidney organoids are poised to become a transformative testing platform, recapitulating human renal injury in vitro and enabling higher-throughput screening of protective interventions. Clinically, the field must shift from reactive rescue to proactive, risk-adapted nephroprotection guided by novel biomarkers and integrated prediction models, and trials must adopt durable endpoints such as one-year estimated glomerular filtration rate slope and chronic kidney disease progression rather than short-term creatinine changes. For now, cell-based and cell-derived therapies remain emerging translational candidates rather than established treatments, but they offer something oncology has lacked: a conceptual framework for protecting the kidney without surrendering the cure.

Subject of Research: Cell-based and cell-derived renoprotective strategies for kidney injury caused by anticancer therapies

Article Title: Cell-based and cell-derived strategies for anticancer therapy-related renal injury: progress, challenges, and translational perspectives

Article References: Chen, Z., Xie, Y., Sun, H., & Liu, M. (2026). Cell-based and cell-derived strategies for anticancer therapy-related renal injury: progress, challenges, and translational perspectives. Holistic Integrative Oncology, 5(1), Article 61. https://doi.org/10.1007/s44178-026-00284-7

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00284-7

Keywords: onco-nephrology, acute kidney injury, mesenchymal stem cells, exosomes, renal progenitor cells, cisplatin nephrotoxicity, immune checkpoint inhibitors, CAR-T therapy, kidney organoids, cell therapy, renal fibrosis, extracellular vesicles